Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-PKD trial of dapagliflozin in autosomal dominant polycystic kidney disease
NL-OMON59315Phase 3Recruiting
- Sponsor
- University of Cologne
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dapagliflozin in autosomal dominant polycystic kidney disease (ADPKD), sponsored by University of Cologne. Primary endpoint: Annual slope of eGFR decline on treatment. Started May 2026; status: recruiting.
02
Drugs
dapagliflozin
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NL-OMON59315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59315.